Cygnus Capital Advisors’s Cytokinetics CYTK Stock Holding History

Cygnus Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-229	Closed	-$15	–	136
2025 Q4	$15	Buy	+229	New	+$14.2K	0.01%	78

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cygnus Capital Advisors's CYTK Position: Q1 2026 in Review

Cygnus Capital Advisors sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 229 shares — an estimated $15 sold.

Cygnus Capital Advisors first reported a position in CYTK in Q4 2025 and held it in 1 quarter. The position peaked at $15 in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Cygnus Capital Advisors reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Cygnus Capital Advisors sold 229 Cytokinetics shares in Q1 2026, an estimated $15.
Cygnus Capital Advisors first reported a position in Cytokinetics in Q4 2025 and held it in 1 quarter.
Cygnus Capital Advisors's Cytokinetics position peaked at $15 in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.